The EIC Accelerator offers non-dilutive funding up to €2.5M, matching the venture's target range. The venture's AI-driven drug resistance prediction aligns with EIC's strategic technology priorities, and the founder's EU location (Île-de-France) qualifies. However, the venture is pre-incorporation, which may be a hurdle for EIC's typical requirement for a registered company.